BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nanjing Immunophage Biotech readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Nanjing Immunophage Biotech's dru
 gs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07937501-80@assetmemo.bio
DTSTAMP:20261121T005947Z
DTSTART;VALUE=DATE:20281120
DTEND;VALUE=DATE:20281121
SUMMARY:IPG11406: Phase 2 readout est. (NCT07937501)
DESCRIPTION:IPG11406\, phase 2.\nStudy: A Study of IPG11406 Tablets in Part
 icipants With Lupus Nephritis\nEstimated primary completion: 20 November 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ipg11406#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07937501
URL:https://assetmemo.bio/drug/ipg11406#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07535489-80@assetmemo.bio
DTSTAMP:20261121T005947Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:IPG11406: Phase 2 readout est. (NCT07535489)
DESCRIPTION:IPG11406\, phase 2\, Ulcerative Colitis.\nStudy: Efficacy and S
 afety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Pha
 se 2)\nEstimated primary completion: 1 December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ipg11406#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07535489
URL:https://assetmemo.bio/drug/ipg11406#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
